Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 1598-1599, 2008; 10.1373/clinchem.2008.112896
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tsui, N. B. Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tsui, N. B. Y.
(Clinical Chemistry. 2008;54:1598-1599.)
© 2008 American Association for Clinical Chemistry, Inc.

Editorials

Multiple Thiopurine S-Methyltransferase Variation Detection: A Step toward Personalized Medicine

Nancy B. Y. Tsui

Li Ka Shing Institute of Health Sciences and, Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China

Address correspondence to the author at:, Li Ka Shing Institute of Health Sciences, and Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China, Fax +852 3142-9172, E-mail nancytsui@cuhk.edu.hk

The first 20% of the full text of this article appears below.

Genetic polymorphisms play an important role in the variability of drug responses among individuals(1). For thiopurine medications, the enzymatic activity of thiopurine S-methyltransferase (TPMT)1 inactivates thiopurine drugs and is influenced by polymorphisms within the TPMT2 gene(2). Currently, more than 20 single-nucleotide polymorphisms (SNPs) have been associated with decreased TPMT activity(2). Patients inheriting 2 nonfunctional alleles have undetectable TPMT activity, and standard doses of thiopurines may lead to life-threatening drug toxicities in such patients. To avoid toxicity, investigators have recommended TPMT genotyping to individually tailor the starting drug dosage(2).

In this issue of Clinical Chemistry, Schaeffeler et al. describe the development of a high-throughput genotyping method that can simultaneously detect 22 TPMT polymorphisms affecting TPMT activity(3). Their method consists of 16-plex and 7-plex SNP assays with single-base primer extension and MALDI-TOF mass spectrometric analysis to achieve a high level of multiplexing. All genotypes were correctly detected in control DNA samples and with synthetic templates of known genotypes. In addition, 586 clinical samples were genotyped, and the results were fully concordant with those obtained with denaturing HPLC(3)(4).

The comprehensive genotyping assay . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.